Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia

Ítems similars

• Treating ‘osteoporosis’: a near miss in an unusual case of FGF-23-mediated hypophosphataemic osteomalacia
  per: Mike Lin, et al.
  Publicat: (2022-11-01)
• A Rare Case of Hypophosphataemic Osteomalacia in von Recklinghausen Neurofibromatosis
  per: Yasmine Makhlouf, et al.
  Publicat: (2021-05-01)
• Tumour-induced osteomalacia: 18 months of 2-weekly burosumab treatment
  per: L Aliberti, et al.
  Publicat: (2023-01-01)
• Burosumab - new potent treatment for X-linked hypophosphatemia and tumor-induced osteomalacia
  per: Magda Wojtuś, et al.
  Publicat: (2023-07-01)
• Selective blood sampling for FGF-23 in tumor-induced osteomalacia
  per: Hans-Christof Schober, et al.
  Publicat: (2017-10-01)